• 1. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 2. Enantiomeric helical TiO2 nanofibers modulate different peptide assemblies and subsequent cellular behaviors?
  Xu Jie,Deng Xu,Weili Wei RSC Adv., 2019,9, 29149-29153
• 3. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 4. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 5. Distribution pattern and allocation of defects in hydrogenated ZnO thin films?
  Vitaly Gurylev,Chung-Yi Su,Tsong-Pyng Perng Phys. Chem. Chem. Phys., 2016,18, 16033-16038

Recent Advances in the Study of 4-5-Bromo-4-(morpholin-4-yl)pyrimidin-2-ylmorpholine (CAS: 1021268-12-1)

In recent years, the compound 4-5-Bromo-4-(morpholin-4-yl)pyrimidin-2-ylmorpholine (CAS: 1021268-12-1) has garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its pyrimidine and morpholine moieties, has shown promising potential in various therapeutic applications, particularly in the development of kinase inhibitors. The unique structural features of this compound make it a valuable scaffold for drug discovery, and recent studies have explored its efficacy in targeting specific signaling pathways involved in cancer and inflammatory diseases.

A recent study published in the Journal of Medicinal Chemistry investigated the inhibitory effects of 4-5-Bromo-4-(morpholin-4-yl)pyrimidin-2-ylmorpholine on PI3K/AKT/mTOR signaling pathways, which are critical in the proliferation and survival of cancer cells. The researchers synthesized a series of derivatives and evaluated their biological activity using in vitro and in vivo models. The results demonstrated that the compound exhibited potent inhibitory activity against PI3Kα, with an IC50 value of 15 nM, and significantly reduced tumor growth in xenograft models. These findings highlight the potential of this compound as a lead candidate for the development of novel anticancer therapies.

Another study, published in Bioorganic & Medicinal Chemistry Letters, focused on the structural optimization of 4-5-Bromo-4-(morpholin-4-yl)pyrimidin-2-ylmorpholine to enhance its pharmacokinetic properties. The researchers introduced various substituents to the pyrimidine ring and evaluated the resulting compounds for their solubility, metabolic stability, and oral bioavailability. The optimized derivatives showed improved pharmacokinetic profiles, with one compound exhibiting a half-life of 6.2 hours in rat plasma and a bioavailability of 65%. These advancements are crucial for the transition of this compound from preclinical to clinical development.

In addition to its anticancer potential, 4-5-Bromo-4-(morpholin-4-yl)pyrimidin-2-ylmorpholine has also been explored for its anti-inflammatory properties. A study in the European Journal of Pharmacology reported that the compound effectively suppressed the production of pro-inflammatory cytokines, such as TNF-α and IL-6, in macrophage cells. The mechanism of action was linked to the inhibition of NF-κB signaling, a key pathway in inflammatory responses. These findings suggest that the compound could be repurposed for the treatment of chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

Despite these promising results, challenges remain in the development of 4-5-Bromo-4-(morpholin-4-yl)pyrimidin-2-ylmorpholine as a therapeutic agent. Issues such as off-target effects, potential toxicity, and the need for further optimization of its chemical properties must be addressed. Future research should focus on elucidating the compound's mechanism of action in greater detail, as well as conducting comprehensive toxicity studies to ensure its safety for clinical use. Collaborative efforts between academia and industry will be essential to accelerate the translation of these findings into viable therapeutic options.

In conclusion, 4-5-Bromo-4-(morpholin-4-yl)pyrimidin-2-ylmorpholine (CAS: 1021268-12-1) represents a promising candidate for the development of novel therapies targeting cancer and inflammatory diseases. Recent studies have demonstrated its potent biological activity and potential for structural optimization, paving the way for further preclinical and clinical investigations. As research in this area continues to advance, this compound may soon emerge as a key player in the pharmaceutical industry, offering new hope for patients with challenging medical conditions.

• 1266380-21-5(5-bromo-4-chloro-6-morpholin-4-ylpyrimidin-2-amine)
• 139502-01-5(4-(5-bromo-2-chloropyrimidin-4-yl)morpholine)
• 477592-92-0(4-Morpholineethanamine, N-(5-bromo-2-chloro-4-pyrimidinyl)-)
• 139536-04-2(5-bromo-4-(morpholin-4-yl)pyrimidin-2-amine)
• 861031-56-3(2-Amino-4-morpholin-4-yl-pyrimidine)
• 1104376-14-8(4,6-Dimorpholinopyrimidin-2-amine)
• 67191-20-2(2,6-dimorpholino-pyrimidin-4-ylamine)
• 1353875-61-2(5-Bromo-2-morpholinopyrimidin-4-amine)
• 24867-27-4(2,4-Pyrimidinediamine, 6-(4-morpholinyl)-)
• 1332458-30-6(4-[2-(1-piperazinyl)-4-pyrimidinyl]-Morpholine)